Robyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.
Robyn M. Scherber, MD, MPH, a physician at Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discussesher advice for treating patients with myelofibrosis(MF) that become refractory or resistant to ruxolitinib (Jakifi).
Ruxolitinib should be maximized in patients with MF as it is known to have spleen response, symptom response, and patients also tend to feel better on it. Scherber says optimizing ruxolitinib is key. However, she has seen physicians try to dose down at the first sign of concerning anemia. Erythropoietin or danazol can be used to help treat anemia in these patients.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More